Charter
People
Creations
Perspectives
Governance
Contact Us
Investor Login
EN
EN
JP
Our Perspectives
View all
Catalys Pacific News
Portfolio News
September 12, 2023
Arialys Therapeutics Launches to Lead the Development of New Precision Medicines for Autoimmune Neuropsychiatric Diseases
September 10, 2023
Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension
August 18, 2023
Catalys Pacific Adds Experienced Pharmaceutical Executive as Advisor
July 7, 2023
Catalys Pacific Adds Experienced Pharmaceutical and Biotech Executive as Advisor
February 14, 2023
Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 9, 2023
Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering
January 24, 2023
Aculys Pharma Initiates a Phase 3 Trial of pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome
January 18, 2023
Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies
January 8, 2023
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
November 10, 2022
Aculys Pharma initiates a phase 3 clinical study of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures
November 8, 2022
Aculys Pharma initiates a phase 3 clinical study of the histamine H3 receptor antagonist/inverse agonist pitolisant in patients with narcolepsy in Japan
May 3, 2022
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
May 3, 2022
HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 2, 2022
HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants
March 30, 2022
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
March 28, 2022
Aculys Pharma Closes US$24 Million Series B Financing
March 23, 2022
Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company
March 10, 2022
Catalys Pacific Calls for Economical Disengagement from Russian Industry
March 2, 2022
Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease
February 17, 2022
Catalys Pacific Adds Experienced Pharmaceutical Executive to Life Sciences Team
February 4, 2022
Aculys Pharma Initiated a Phase 1 Clinical Trial of pitolisant, a histamine H3 receptor antagonist / inverse agonist, in Japan
January 26, 2022
Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO®
October 29, 2021
Aculys Pharma Closes US$60 Million Series A Financing Led by SoftBank Vision Fund 2
October 18, 2021
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
October 4, 2021
Catalys Pacific Strengthens Company Creation Team with New Operating Partner
September 8, 2021
Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
September 8, 2021
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate
August 9, 2021
Remembering Catalys Pacific Industry Advisor Tadataka ‘Tachi’ Yamada, MD (1945-2021)
April 29, 2021
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
April 6, 2021
Mineralys Therapeutics Closes $40 Million Series A Funding
January 19, 2021
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
November 30, 2020
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
November 4, 2020
Catalys Pacific Strengthens Company Creation Team with New Operating Partner
July 16, 2020
Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists
June 19, 2020
Catalys Pacific Strengthens Company Creation Team with New Industry Advisor
October 24, 2019
Phathom Pharmaceuticals Announces Pricing of Initial Public Offering and Begin trading on the Nasdaq
July 23, 2019
Japanese Foreign Minister’s Commendations for FY 2019 to Dr. Slingsby, Founder & Managing Partner of Catalys Pacific
June 17, 2019
Catalys Pacific Launches in Japan to Advance Early-Stage Life Sciences Innovation by Creating and Investing in Global Companies
May 14, 2019
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals
Creations
View all
Phathom Pharmaceuticals
Going beyond to advance treatments for patients with acid-related disorders
HilleVax
Advancing the Development of a Vaccine to Protect against Norovirus Infection
OUR CREW
Learn more